Quince Therapeutics, Inc.
$1.36
+0.0000%Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.0).
Valuation inputs: P/E -1.0, earnings yield N/A, momentum 0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.9%, ROIC -53.4%).
Profitability stack: net margin 0.0%, ROE -1.9%, ROIC -53.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +73.7%, momentum 0.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Quince Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Quince Therapeutics, Inc. Fair Value Envelope
No Revenue Data
QNCX has not reported any revenue values in the available annual periods.
Quince Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
QNCX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
QNCX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
QNCX has not reported any net profit margin values in the available annual periods.
Quince Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Quince Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Quince Therapeutics, Inc. Street Expectations Map
No Target Data
No analyst price targets available for qncx.
Quince Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $441K and sold $174K worth of QNCX shares, resulting in $268K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
50.0K
173.50K
-174K
-$174K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
385.2K
441.48K
0
0.00
+441K
+$441K
Top Buyers
Thye Dirk
Director, Officer: Ceo And Cmo
$181K
Hannah Brendan
Officer: Cbo, Coo & Cco
$45K
Benatti Luca
Director
$29K
Senner Christopher J.
Director
$29K
Lamond David
Director
$29K
Top Sellers
Benatti Luca
Director
$174K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $268K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
QNCX has not reported any dividend yield values in the available annual periods.
qncx Dividend History
Learning Layer
Related Guides
Build conviction on QNCX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.